These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20846303)

  • 1. The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role?
    Mukhopadhyay A; Do DV; Ong CT; Khoo YT; Masilamani J; Chan SY; Vincent AS; Wong PK; Lim CP; Cao X; Lim IJ; Phan TT
    Br J Dermatol; 2011 Feb; 164(2):372-86. PubMed ID: 20846303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
    Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
    Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
    Reber L; Da Silva CA; Frossard N
    Eur J Pharmacol; 2006 Mar; 533(1-3):327-40. PubMed ID: 16483568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells.
    Babina M; Rex C; Guhl S; Thienemann F; Artuc M; Henz BM; Zuberbier T
    Exp Dermatol; 2006 Jul; 15(7):530-7. PubMed ID: 16761962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of hepatocyte growth factor/c-Met system in keloid pathogenesis.
    Mukhopadhyay A; Fan S; Dang VD; Khoo A; Ong CT; Lim IJ; Phan TT
    J Trauma; 2010 Dec; 69(6):1457-66. PubMed ID: 21150524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway.
    Hollenbeck ST; Sakakibara K; Faries PL; Workhu B; Liu B; Kent KC
    J Surg Res; 2004 Aug; 120(2):288-94. PubMed ID: 15234225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndecan-2 and decorin: proteoglycans with a difference--implications in keloid pathogenesis.
    Mukhopadhyay A; Wong MY; Chan SY; Do DV; Khoo A; Ong CT; Cheong HH; Lim IJ; Phan TT
    J Trauma; 2010 Apr; 68(4):999-1008. PubMed ID: 20386290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dermal stem cell factor and c-kit are overexpressed in melasma.
    Kang HY; Hwang JS; Lee JY; Ahn JH; Kim JY; Lee ES; Kang WH
    Br J Dermatol; 2006 Jun; 154(6):1094-9. PubMed ID: 16704639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
    Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of c-Kit receptor and stem cell factor in cerebellar inhibitory synapses in response to kainic acid.
    Kim D; Im JO; Won YJ; Yoon SY; Lee EJ; Lee JH; Hong HN
    J Neurosci Res; 2003 Jan; 71(1):72-8. PubMed ID: 12478615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression.
    Shaw TJ; Keszthelyi EJ; Tonary AM; Cada M; Vanderhyden BC
    Exp Cell Res; 2002 Feb; 273(1):95-106. PubMed ID: 11795950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
    Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
    Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.
    Re D; Wickenhauser C; Ahmadi T; Buchdunger E; Kochanek M; Diehl V; Wolf J
    Br J Cancer; 2002 Apr; 86(8):1333-5. PubMed ID: 11953894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
    Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
    Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B; Tirnitz-Parker JE; Olynyk JK
    Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury.
    Wang CH; Verma S; Hsieh IC; Hung A; Cheng TT; Wang SY; Liu YC; Stanford WL; Weisel RD; Li RK; Cherng WJ
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):540-7. PubMed ID: 17204664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
    J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.